purine nucleotide interconversion enzymes Inhibitors
2 drugsAbout purine nucleotide interconversion enzymes
Purine nucleotide interconversion enzymes are essential for synthesizing and maintaining cellular purine nucleotide pools, the building blocks of DNA and RNA. They catalyze the interconversion of different purine nucleotides, ensuring the correct balance for various cellular processes.
Targeting these enzymes is a viable strategy in oncology due to the high demand for nucleotide synthesis in rapidly dividing cancer cells. Disrupting purine nucleotide metabolism can selectively inhibit cancer cell growth, though no genetic evidence directly links these enzymes to specific diseases.
Two FDA-approved drugs, PURIXAN and PURINETHOL, target purine nucleotide interconversion enzymes in oncology. Both drugs are small molecules, developed by NOVA LABS LTD and STASON PHARMS respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Refractory Acute Lymphoblastic Leukemia with only 2 trials.
- phase2 represents biological uncertainty with 42% completion.
Top purine nucleotide interconversion enzymes Drugs
The competitive landscape consists of two companies, NOVA LABS LTD and STASON PHARMS.
Low market concentration suggests relatively low barriers to entry for new competitors.
purine nucleotide interconversion enzymes Drug Modality Landscape
Modalities
Routes of Administration
purine nucleotide interconversion enzymes is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs represents a whitespace opportunity.
purine nucleotide interconversion enzymes Clinical Trials 86 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 5 | 2 | 8 | 71% |
| Phase 2 | 44 | 12 | 7 | 25 | 63% |
| Phase 3 | 23 | 10 | 0 | 13 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
purine nucleotide interconversion enzymes Drug Approval Timeline (1953 - 2014)
The approval timeline spans 62 years, from PURINETHOL (1953) to PURIXAN (2014).
The long approval gap indicates potential saturation or challenges in developing new drugs in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 63 clinical trials targeting purine nucleotide interconversion enzymes.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities